Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,341 to 1,360 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| aQIV vs Non-influenza Comparator Vaccine: deaths from any cause | 33 of 3,380 34 of 3,377 | -0.0 points -0.5 to 0.5 | 6,757 | NCT02587221 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age |
| aQIV vs Non-influenza Comparator Vaccine: serious adverse events | 238 of 3,380 234 of 3,377 | 0.1 points -1.1 to 1.3 | 6,757 | NCT02587221 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age |
| Immediate Return of Results (Intent to Treat, ITT) vs Delayed Return of Results (Intent to Treat, ITT): deaths from any cause | 13 of 3,380 12 of 3,374 | 0.0 points -0.3 to 0.3 | 6,754 | NCT04191824 Genetic Testing to Understand and Address Renal Disease Disparities Across the United States |
| Intervention: Diagnostic Algorithm vs Usual Care: Additional Investigations at Index Consultation and/or During Follow-up | 335 of 2,988 517 of 3,762 | -2.5 points -4.1 to -0.9 | 6,750 | NCT04470518 Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project |
| Intervention: Diagnostic Algorithm vs Usual Care: Clinical Recovery at Day 30 | 2,967 of 2,988 3,747 of 3,762 | -0.3 points -0.7 to 0.1 | 6,750 | NCT04470518 Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project |
| Intervention: Diagnostic Algorithm vs Usual Care: Admission to Hospital at Day 0 | 7 of 2,988 11 of 3,762 | -0.1 points -0.3 to 0.2 | 6,750 | NCT04470518 Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project |
| Intervention: Diagnostic Algorithm vs Usual Care: Additional Testing at Index Consultation | 249 of 2,988 400 of 3,762 | -2.3 points -3.7 to -0.9 | 6,750 | NCT04470518 Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project |
| Intervention: Diagnostic Algorithm vs Usual Care: Admission to Hospital During Follow-up | 25 of 2,988 53 of 3,762 | -0.6 points -1.1 to -0.1 | 6,750 | NCT04470518 Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project |
| Intervention: Diagnostic Algorithm vs Usual Care: Referral to Hospital at Day 0 | 24 of 2,988 13 of 3,762 | 0.5 points 0.1 to 0.9 | 6,750 | NCT04470518 Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project |
| Intervention: Diagnostic Algorithm vs Usual Care: Additional Testing During Follow-up | 111 of 2,988 149 of 3,762 | -0.2 points -1.2 to 0.7 | 6,750 | NCT04470518 Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project |
| Intervention: Diagnostic Algorithm vs Usual Care: Referral to Hospital During Follow-up | 79 of 2,988 84 of 3,762 | 0.4 points -0.3 to 1.2 | 6,750 | NCT04470518 Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project |
| Intervention: Diagnostic Algorithm vs Usual Care: Re-consultation During Follow-up | 770 of 2,988 968 of 3,762 | 0.0 points -2.1 to 2.1 | 6,750 | NCT04470518 Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project |
| Intervention: Diagnostic Algorithm vs Usual Care: Clinical Recovery at Day 7 | 2,539 of 2,988 3,200 of 3,762 | -0.1 points -1.8 to 1.6 | 6,750 | NCT04470518 Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project |
| Intervention: Diagnostic Algorithm vs Usual Care: Antibiotic Prescribing Rate During Follow-up | 291 of 2,988 429 of 3,762 | -1.7 points -3.1 to -0.2 | 6,750 | NCT04470518 Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project |
| Intervention: Diagnostic Algorithm vs Usual Care: Antibiotic Prescribing Rate at Index Consultation (Immediate or Delayed) | 466 of 2,988 817 of 3,762 | -6.1 points -8.0 to -4.3 | 6,750 | NCT04470518 Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project |
| Double-blind Phase: Ad26.COV2.S 5*10^10 vp vs Double-blind Phase: Placebo: Number of Participants With Solicited Local Adverse Events (AEs) During 7 Days Following Vaccination (Double Blind Phase) | 1,839 of 3,356 684 of 3,379 | 34.6 points 32.4 to 36.7 | 6,735 | NCT04505722 A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants |
| Double-blind Phase: Ad26.COV2.S 5*10^10 vp vs Double-blind Phase: Placebo: Number of Participants With Unsolicited AEs During 28 Days Post-vaccination (Double Blind Phase) | 456 of 3,356 422 of 3,379 | 1.1 points -0.5 to 2.7 | 6,735 | NCT04505722 A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants |
| Double-blind Phase: Ad26.COV2.S 5*10^10 vp vs Double-blind Phase: Placebo: Number of Participants With Solicited Systemic AEs During 7 Days Following Vaccination (Double Blind Phase) | 2,021 of 3,356 1,307 of 3,379 | 21.5 points 19.2 to 23.9 | 6,735 | NCT04505722 A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants |
| ProQuad® Arm: Dose 2 vs ProQuad® Arm: Dose 1: serious adverse events | 22 of 3,342 40 of 3,376 | -0.5 points -1.0 to -0.1 | 6,718 | NCT00560755 Safety Study of ProQuad® rHA in Infants (V221-037) |
| Palivizumab vs Motavizumab: Incidence of RSV Hospitalization (Includes Deaths by RSV) | 62 of 3,306 46 of 3,329 | 0.5 points -0.1 to 1.1 | 6,635 | NCT00129766 Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=68
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02587221-deaths",
"title": "aQIV vs Non-influenza Comparator Vaccine: deaths from any cause",
"summary": "33 of 3380 against 34 of 3377; risk difference -0.0 points, 95% interval -0.5 to 0.5; NCT02587221, Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age",
"record": "/library/comparisons/NCT02587221-deaths",
"nct_id": "NCT02587221",
"kind": "deaths",
"participants": 6757,
"risk_difference": {
"value": -0.0003047941785100407,
"lower": -0.005162549695794483,
"upper": 0.0045409157067476365
},
"group_1": "33 of 3,380",
"group_2": "34 of 3,377",
"difference": "-0.0 points",
"interval": "-0.5 to 0.5",
"trial_title": "Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age"
},
{
"id": "NCT02587221-sae",
"title": "aQIV vs Non-influenza Comparator Vaccine: serious adverse events",
"summary": "238 of 3380 against 234 of 3377; risk difference 0.1 points, 95% interval -1.1 to 1.3; NCT02587221, Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age",
"record": "/library/comparisons/NCT02587221-sae",
"nct_id": "NCT02587221",
"kind": "serious-adverse-events",
"participants": 6757,
"risk_difference": {
"value": 0.0011219299367632996,
"lower": -0.011064578411532211,
"upper": 0.013310821606576234
},
"group_1": "238 of 3,380",
"group_2": "234 of 3,377",
"difference": "0.1 points",
"interval": "-1.1 to 1.3",
"trial_title": "Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=69",
"request_id": "UIBMk0srp3_sFryW"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant